Hub : Traits :

Current tobacco smoking

58 significantly associated models · 37 unique genes.

Significant Loci

#	chr	p0	p1	# assoc genes	# joint genes	best TWAS P	best SNP P	cond SNP P	% var exp	joint genes
1	7	116660803	118207833	1	1	6.4e-08	2.1e-08	5.4e-02	88	CTTNBP2
2	8	27205777	27720371	1	1	3.9e-09	1.2e-08	1.0e-02	80	CLU
3	8	91282507	92689456	1	1	1.8e-07	2.3e-06	1.8e-03	56	RP11-122A3.2
4	9	126946822	129422783	8	2	2.8e-10	2.7e-08	9.1e-01	100	MAPKAP1 PRPS1P2
5	9	135521303	136922700	2	1	7.5e-09	1.7e-23	7.5e-19	21	SURF1
6	10	103550604	105647095	4	2	3.8e-08	1.1e-07	1.8e-01	94	C10orf32 NT5C2
7	12	120242845	121660787	1	1	2.3e-07	1.6e-04	5.1e-01	97	COQ5
8	14	103483881	105007585	2	1	6.7e-08	5.7e-07	6.2e-02	86	PPP1R13B
9	15	46780520	48764942	1	1	4.1e-08	6.1e-08	4.5e-04	58	SEMA6D
10	17	78843139	79380547	1	1	6.9e-08	1.8e-07	1.0e+00	100	AATK
11	19	41034912	41537868	1	1	9.3e-09	1.5e-06	1.7e-04	39	RAB4B
12	20	61576647	62912463	5	1	2.0e-08	7.3e-08	3.4e-01	97	RTEL1
13	22	41181586	42907619	8	1	8.4e-10	3.3e-08	2.1e-01	95	PHF5A

Pleiotropic Associations

Trait	chisq ratio	# genes⁺	# genes⁺⁺	% genes⁺⁺	corr	corr P	genes
Smoking Status	18.02	14	9	20.0	0.96	3.5e-08	AATK C10orf32 CLU COQ5 CTTNBP2 MAPKAP1 NT5C2 PHF5A PPP1R13B PRPS1P2 RP11-122A3.2 RTEL1 SEMA6D SURF1
Smoking status: Current	17.76	15	9	20.0	1.00	3.8e-17	AATK C10orf32 CLU COQ5 CTTNBP2 MAPKAP1 NT5C2 PHF5A PPP1R13B PRPS1P2 RAB4B RP11-122A3.2 RTEL1 SEMA6D SURF1
Ever smoked	8.38	5	4	8.9	0.98	3.9e-03	AATK C10orf32 CTTNBP2 NT5C2 PRPS1P2
Past tobacco smoking	8.37	6	3	6.7	-0.76	7.8e-02	C10orf32 CLU CTTNBP2 NT5C2 PRPS1P2 RAB4B
Maternal smoking around birth	6.30	4	0	0.0	0.99	1.3e-02	C10orf32 NT5C2 PHF5A PPP1R13B
Pack years adult smoking proportion	6.26	5	1	2.2	0.47	4.3e-01	MAPKAP1 PPP1R13B RAB4B SEMA6D SURF1
Pack years of smoking	6.06	4	1	2.2	0.41	5.9e-01	PPP1R13B RAB4B SEMA6D SURF1
Prostate Cancer	4.60	1	1	2.2	0.00	1.0e+00	RTEL1
Smoking status: Previous	4.60	3	0	0.0	0.00	1.0e+00	C10orf32 NT5C2 RAB4B
Exposure to tobacco smoke outside home	4.38	2	0	0.0	0.00	1.0e+00	C10orf32 CTTNBP2
Worrier / anxious feelings	4.09	3	1	2.2	0.00	1.0e+00	C10orf32 NT5C2 PHF5A
Worry (Nagel 2018)	4.08	4	2	4.4	-0.18	8.2e-01	AATK C10orf32 NT5C2 PRPS1P2
Alcohol usually taken with meals	4.07	3	0	0.0	0.00	1.0e+00	CLU CTTNBP2 NT5C2
Townsend deprivation index at recruitment	4.06	4	0	0.0	0.98	1.7e-02	C10orf32 CTTNBP2 MAPKAP1 PRPS1P2
Neuroticism (Nagel 2018)	3.97	5	1	2.2	-0.34	5.8e-01	AATK C10orf32 CTTNBP2 PHF5A PRPS1P2
Neuroticism	3.66	5	1	2.2	-0.22	7.2e-01	AATK C10orf32 CTTNBP2 PHF5A PRPS1P2
Alcohol intake versus 10 years previously	3.66	3	1	2.2	0.00	1.0e+00	CLU CTTNBP2 NT5C2
Major Depression (MDD)	3.49	1	0	0.0	0.00	1.0e+00	CTTNBP2
Pulse rate, automated reading	3.48	3	1	2.2	0.00	1.0e+00	MAPKAP1 RP11-122A3.2 RTEL1
Sensitivity / hurt feelings	3.43	3	0	0.0	0.00	1.0e+00	AATK MAPKAP1 PRPS1P2
Financial difficulties in last 2 years	3.33	1	0	0.0	0.00	1.0e+00	PPP1R13B
Neuroticism score	3.32	4	1	2.2	-0.55	4.5e-01	AATK CTTNBP2 PHF5A PRPS1P2
Frequency of tiredness / lethargy in last 2 weeks	3.32	4	0	0.0	-0.51	4.9e-01	AATK PHF5A PPP1R13B PRPS1P2
Nervous feelings	3.31	3	1	2.2	0.00	1.0e+00	AATK C10orf32 PRPS1P2
Mouth/teeth dental problems	3.28	2	0	0.0	0.00	1.0e+00	AATK PRPS1P2
Irritable Bowel Disease (IBD)	3.18	1	1	2.2	0.00	1.0e+00	RTEL1
Frequency of unenthusiasm / disinterest in last 2 weeks	3.13	2	0	0.0	0.00	1.0e+00	AATK CTTNBP2
Risk taking	3.08	2	0	0.0	0.00	1.0e+00	NT5C2 PPP1R13B
Crohns Disease (2017)	3.07	2	1	2.2	0.00	1.0e+00	PHF5A RTEL1
Allergy	3.07	2	2	4.4	0.00	1.0e+00	PHF5A RTEL1
Overall health rating	3.06	3	0	0.0	0.00	1.0e+00	AATK MAPKAP1 PRPS1P2
Seen doctor (GP) for nerves, anxiety, tension or depression	3.01	3	0	0.0	0.00	1.0e+00	AATK CTTNBP2 PRPS1P2
Crohns Disease (2012)	2.97	1	1	2.2	0.00	1.0e+00	RTEL1
Allergy or Eczema	2.91	3	2	4.4	0.00	1.0e+00	NT5C2 PHF5A RTEL1
Wheeze or whistling in the chest in last year	2.89	1	0	0.0	0.00	1.0e+00	RTEL1
Qualifications: College or University degree	2.89	6	1	2.2	-0.99	3.2e-04	C10orf32 CTTNBP2 NT5C2 PRPS1P2 RTEL1 SEMA6D
Mouth/teeth dental problems: Dentures	2.86	1	0	0.0	0.00	1.0e+00	CLU
Schizophrenia (2018)	2.83	3	1	2.2	0.00	1.0e+00	C10orf32 CLU PPP1R13B
Hayfever, allergic rhinitis or eczema	2.75	3	2	4.4	0.00	1.0e+00	NT5C2 PHF5A RTEL1
Seen a psychiatrist for nerves, anxiety, tension or depression	2.75	2	0	0.0	0.00	1.0e+00	CTTNBP2 PRPS1P2
Bipolar Disorder or Schizophrenia	2.70	2	1	2.2	0.00	1.0e+00	C10orf32 PPP1R13B
Schizophrenia (2014)	2.68	3	1	2.2	0.00	1.0e+00	C10orf32 CLU PPP1R13B
Lung cancer (father)	2.68	1	0	0.0	0.00	1.0e+00	CLU
Respiratory disease	2.65	2	1	2.2	0.00	1.0e+00	PHF5A RTEL1
Mother's age at death	2.64	1	0	0.0	0.00	1.0e+00	MAPKAP1
Number of incorrect matches in round	2.61	2	0	0.0	0.00	1.0e+00	C10orf32 NT5C2
Tense / 'highly strung'	2.60	2	0	0.0	0.00	1.0e+00	AATK PHF5A
Neuroticism (2016)	2.59	1	0	0.0	0.00	1.0e+00	AATK
Irritability	2.59	1	0	0.0	0.00	1.0e+00	PHF5A
Long-standing illness, disability or infirmity	2.56	1	0	0.0	0.00	1.0e+00	CLU
Number of self-reported non-cancer illnesses	2.56	2	0	0.0	0.00	1.0e+00	PHF5A RTEL1
Mood swings	2.55	2	0	0.0	0.00	1.0e+00	CTTNBP2 PHF5A
Hand grip strength (right)	2.50	4	1	2.2	-0.16	8.4e-01	C10orf32 MAPKAP1 NT5C2 PRPS1P2
Peak expiratory flow (PEF)	2.50	3	1	2.2	0.00	1.0e+00	C10orf32 CTTNBP2 PRPS1P2
Frequency of depressed mood in last 2 weeks	2.48	1	0	0.0	0.00	1.0e+00	AATK
Lung FVC	2.46	3	1	2.2	0.00	1.0e+00	CTTNBP2 PRPS1P2 RTEL1
Suffer from 'nerves'	2.43	2	0	0.0	0.00	1.0e+00	AATK C10orf32
Depression (Nagel 2018)	2.42	1	0	0.0	0.00	1.0e+00	AATK
Hand grip strength (left)	2.41	4	0	0.0	-0.07	9.3e-01	C10orf32 MAPKAP1 NT5C2 PRPS1P2
Depressed Affect (Nagel 2018)	2.40	3	1	2.2	0.00	1.0e+00	AATK CTTNBP2 PHF5A
Medication: Ventolin 100micrograms inhaler	2.40	1	0	0.0	0.00	1.0e+00	PHF5A
Guilty feelings	2.40	1	0	0.0	0.00	1.0e+00	AATK
Type 2 Diabetes (T2D) (2018)	2.31	1	0	0.0	0.00	1.0e+00	RTEL1
Osteoarthritis (self-reported)	2.30	1	0	0.0	0.00	1.0e+00	MAPKAP1
Fed-up feelings	2.26	3	0	0.0	0.00	1.0e+00	AATK CTTNBP2 PHF5A
Ulcerative Colitis	2.25	1	1	2.2	0.00	1.0e+00	RTEL1
Ulcerative Colitis (UC)	2.24	1	1	2.2	0.00	1.0e+00	RTEL1
Systolic Blood Pressure	2.24	5	2	4.4	-0.69	2.0e-01	C10orf32 COQ5 MAPKAP1 RP11-122A3.2 RTEL1
Forced expiratory volume in 1-second (FEV1)	2.24	3	2	4.4	0.00	1.0e+00	CTTNBP2 PRPS1P2 RTEL1
Ever had bowel cancer screening	2.24	1	0	0.0	0.00	1.0e+00	SURF1
Diastolic blood pressure, automated reading	2.21	3	1	2.2	0.00	1.0e+00	MAPKAP1 NT5C2 RTEL1
Pulse rate	2.19	1	0	0.0	0.00	1.0e+00	MAPKAP1
Blood White Count	2.17	7	4	8.9	0.99	4.7e-05	AATK C10orf32 NT5C2 PPP1R13B RTEL1 SEMA6D SURF1
Leg fat percentage (left)	2.17	3	1	2.2	0.00	1.0e+00	MAPKAP1 RP11-122A3.2 RTEL1
Qualifications: None of the above	2.16	1	0	0.0	0.00	1.0e+00	SEMA6D
Worry too long after embarrassment	2.14	2	0	0.0	0.00	1.0e+00	CTTNBP2 PRPS1P2
Illness, injury, bereavement, stress in last 2 years	2.13	1	0	0.0	0.00	1.0e+00	CTTNBP2
Frequency of tenseness / restlessness in last 2 weeks	2.10	1	0	0.0	0.00	1.0e+00	AATK
Diabetes (mother)	2.08	1	0	0.0	0.00	1.0e+00	COQ5
Father's age at death	2.07	1	0	0.0	0.00	1.0e+00	CLU
Medication for pain relief, constipation, heartburn	2.07	1	0	0.0	0.00	1.0e+00	PRPS1P2
Qualifications: A levels/AS levels or equivalent	2.04	2	0	0.0	0.00	1.0e+00	CTTNBP2 SEMA6D
Forced vital capacity (FVC)	2.03	2	2	4.4	0.00	1.0e+00	PRPS1P2 RTEL1
Systolic blood pressure, automated reading	2.02	3	0	0.0	0.00	1.0e+00	C10orf32 MAPKAP1 RTEL1
Forced expiratory volume in 1-second (FEV1), predicted percentage	2.02	2	1	2.2	0.00	1.0e+00	PRPS1P2 RTEL1
Arm fat percentage (right)	1.97	5	0	0.0	0.13	8.4e-01	MAPKAP1 PHF5A PPP1R13B RP11-122A3.2 SEMA6D
Leg fat percentage (right)	1.96	3	0	0.0	0.00	1.0e+00	MAPKAP1 RP11-122A3.2 RTEL1
Birth weight of first child	1.95	1	0	0.0	0.00	1.0e+00	C10orf32
Leg fat mass (left)	1.95	3	0	0.0	0.00	1.0e+00	C10orf32 RP11-122A3.2 RTEL1
Waist circumference	1.94	4	0	0.0	0.99	7.8e-03	C10orf32 PPP1R13B RP11-122A3.2 RTEL1
Pulse wave peak to peak time	1.94	1	0	0.0	0.00	1.0e+00	C10orf32
Arm fat percentage (left)	1.92	5	0	0.0	0.07	9.1e-01	MAPKAP1 PHF5A PPP1R13B RP11-122A3.2 SEMA6D
Pulse wave Arterial Stiffness index	1.87	1	0	0.0	0.00	1.0e+00	C10orf32
Body fat percentage	1.87	4	0	0.0	0.52	4.8e-01	MAPKAP1 PHF5A RP11-122A3.2 RTEL1
Hip circumference	1.86	4	1	2.2	0.23	7.7e-01	C10orf32 PPP1R13B RTEL1 SEMA6D
Leg fat mass (right)	1.85	3	0	0.0	0.00	1.0e+00	C10orf32 RP11-122A3.2 RTEL1
Medication: Amlodipine	1.84	1	0	0.0	0.00	1.0e+00	MAPKAP1
Whole body fat mass	1.84	5	0	0.0	0.17	7.8e-01	C10orf32 PHF5A RP11-122A3.2 RTEL1 SEMA6D
Miserableness	1.84	2	0	0.0	0.00	1.0e+00	AATK CTTNBP2
Alcohol intake frequency.	1.83	1	0	0.0	0.00	1.0e+00	PHF5A
Fractured/broken bones in last 5 years	1.83	1	0	0.0	0.00	1.0e+00	CTTNBP2
Height	1.82	12	7	15.6	-0.36	2.6e-01	AATK C10orf32 CLU COQ5 CTTNBP2 MAPKAP1 NT5C2 PHF5A PPP1R13B PRPS1P2 RP11-122A3.2 RTEL1
Asthma (self-reported)	1.81	2	1	2.2	0.00	1.0e+00	PHF5A RTEL1
Pain experienced in last month	1.79	1	0	0.0	0.00	1.0e+00	PRPS1P2
Trunk fat percentage	1.75	4	1	2.2	-0.12	8.8e-01	PHF5A RP11-122A3.2 RTEL1 SEMA6D
Asthma	1.74	2	1	2.2	0.00	1.0e+00	PHF5A RTEL1
Commuting to job workplace: Car/motor vehicle	1.74	1	0	0.0	0.00	1.0e+00	RP11-122A3.2
Alzheimer’s Disease (including proxy)	1.73	1	0	0.0	0.00	1.0e+00	CLU
BMI	1.72	5	1	2.2	0.73	1.6e-01	C10orf32 MAPKAP1 PPP1R13B RAB4B RP11-122A3.2
Arm fat mass (right)	1.71	5	0	0.0	0.13	8.3e-01	C10orf32 PHF5A PPP1R13B RP11-122A3.2 SEMA6D
Arm fat mass (left)	1.70	5	0	0.0	0.11	8.5e-01	C10orf32 PHF5A PPP1R13B RP11-122A3.2 SEMA6D
Trunk fat mass	1.68	4	0	0.0	-0.34	6.6e-01	C10orf32 PHF5A RTEL1 SEMA6D
Bipolar Disorder (2018)	1.67	1	0	0.0	0.00	1.0e+00	PPP1R13B
Vitamin and mineral supplements	1.64	1	0	0.0	0.00	1.0e+00	NT5C2
Body mass index (BMI)	1.63	3	0	0.0	0.00	1.0e+00	C10orf32 PPP1R13B RP11-122A3.2
Weight	1.61	3	1	2.2	0.00	1.0e+00	C10orf32 NT5C2 PHF5A
Forced expiratory volume in 1-second (FEV1), Best measure	1.61	2	0	0.0	0.00	1.0e+00	PRPS1P2 RTEL1
Standing height	1.59	7	3	6.7	-0.70	7.7e-02	AATK C10orf32 COQ5 MAPKAP1 PHF5A PRPS1P2 RP11-122A3.2
Schizophrenia vs Biploar Disorder	1.58	1	0	0.0	0.00	1.0e+00	CLU
Fluid intelligence score	1.56	2	0	0.0	0.00	1.0e+00	AATK PPP1R13B
Arm predicted mass (right)	1.56	3	1	2.2	0.00	1.0e+00	C10orf32 NT5C2 PRPS1P2
Coronary Artery Disease (CAD)	1.53	1	0	0.0	0.00	1.0e+00	C10orf32
Trunk predicted mass	1.53	4	2	4.4	0.06	9.4e-01	C10orf32 MAPKAP1 NT5C2 PRPS1P2
Medication: Allopurinol	1.53	1	0	0.0	0.00	1.0e+00	RAB4B
Trunk fat-free mass	1.52	4	2	4.4	0.06	9.4e-01	C10orf32 MAPKAP1 NT5C2 PRPS1P2
Arm fat-free mass (right)	1.52	3	1	2.2	0.00	1.0e+00	C10orf32 NT5C2 PRPS1P2
Leg fat-free mass (right)	1.51	2	1	2.2	0.00	1.0e+00	C10orf32 PRPS1P2
Forced expiratory volume in 1-second (FEV1), predicted	1.50	1	0	0.0	0.00	1.0e+00	C10orf32
Leg fat-free mass (left)	1.49	2	1	2.2	0.00	1.0e+00	C10orf32 PRPS1P2
Impedance of arm (left)	1.49	2	1	2.2	0.00	1.0e+00	C10orf32 PHF5A
Leg predicted mass (right)	1.49	2	1	2.2	0.00	1.0e+00	C10orf32 PRPS1P2
Arm fat-free mass (left)	1.49	3	1	2.2	0.00	1.0e+00	C10orf32 NT5C2 PRPS1P2
Leg predicted mass (left)	1.48	2	1	2.2	0.00	1.0e+00	C10orf32 PRPS1P2
Forced vital capacity (FVC), Best measure	1.48	2	1	2.2	0.00	1.0e+00	PRPS1P2 RTEL1
Whole body fat-free mass	1.48	3	2	4.4	0.00	1.0e+00	C10orf32 NT5C2 PRPS1P2
Whole body water mass	1.47	3	2	4.4	0.00	1.0e+00	C10orf32 NT5C2 PRPS1P2
Arm predicted mass (left)	1.47	3	1	2.2	0.00	1.0e+00	C10orf32 NT5C2 PRPS1P2
Waist Hip Ratio (WHR)	1.46	3	0	0.0	0.00	1.0e+00	MAPKAP1 PRPS1P2 SEMA6D
Blood Eosinophil Count	1.45	4	1	2.2	0.24	7.6e-01	AATK PHF5A PPP1R13B SURF1
Basal metabolic rate	1.45	3	1	2.2	0.00	1.0e+00	C10orf32 NT5C2 PRPS1P2
Impedance of whole body	1.42	4	1	2.2	0.55	4.5e-01	C10orf32 PHF5A PPP1R13B PRPS1P2
Chronotype (morning person)	1.40	1	0	0.0	0.00	1.0e+00	PHF5A
Impedance of arm (right)	1.39	3	1	2.2	0.00	1.0e+00	C10orf32 PHF5A RAB4B
Impedance of leg (right)	1.36	5	0	0.0	0.48	4.1e-01	C10orf32 PPP1R13B PRPS1P2 RTEL1 SEMA6D
Impedance of leg (left)	1.36	4	0	0.0	0.63	3.7e-01	PPP1R13B PRPS1P2 RTEL1 SEMA6D
Verbal and Numeric Reasoning (VNR)	1.33	1	0	0.0	0.00	1.0e+00	PPP1R13B
High cholesterol (Self-reported)	1.33	1	0	0.0	0.00	1.0e+00	SURF1
Comparative body size at age 10	1.31	1	0	0.0	0.00	1.0e+00	PHF5A
Basal cell carcinoma (self-reported)	1.26	1	0	0.0	0.00	1.0e+00	PHF5A
Birth weight	1.24	1	0	0.0	0.00	1.0e+00	C10orf32
Age when periods started (menarche)	1.23	1	0	0.0	0.00	1.0e+00	PRPS1P2
Intelligence (Savage-Jansen 2018)	1.19	2	0	0.0	0.00	1.0e+00	AATK PPP1R13B
Medication for hormone replacement therapy	1.19	1	0	0.0	0.00	1.0e+00	RAB4B
Sitting height	1.19	6	0	0.0	-0.39	4.4e-01	AATK C10orf32 MAPKAP1 PRPS1P2 RP11-122A3.2 SURF1
Lung FEV1/FVC ratio	1.18	3	0	0.0	0.00	1.0e+00	C10orf32 CTTNBP2 RAB4B
Heel T-Score	1.17	3	1	2.2	0.00	1.0e+00	PHF5A PPP1R13B RTEL1
Comparative height size at age 10	1.17	3	1	2.2	0.00	1.0e+00	C10orf32 COQ5 MAPKAP1
Cardiovascular Disease	1.14	1	0	0.0	0.00	1.0e+00	MAPKAP1
Hypothyroidism (self reported)	1.10	1	0	0.0	0.00	1.0e+00	PHF5A
Vascular/heart problems diagnosed by doctor	1.09	2	0	0.0	0.00	1.0e+00	MAPKAP1 NT5C2
Blood Platelet Count	0.99	4	2	4.4	0.96	3.9e-02	C10orf32 NT5C2 PHF5A RTEL1
High blood pressure	0.96	1	0	0.0	0.00	1.0e+00	MAPKAP1
Blood Red Count	0.94	4	2	4.4	0.99	9.6e-03	MAPKAP1 PPP1R13B RTEL1 SURF1
Hypertension (Self-reported)	0.94	1	0	0.0	0.00	1.0e+00	MAPKAP1
Breast Cancer	0.85	1	0	0.0	0.00	1.0e+00	CLU
Medication for cholesterol, blood pressure or diabetes	0.84	1	0	0.0	0.00	1.0e+00	MAPKAP1
Medication: Blood pressure	0.82	1	0	0.0	0.00	1.0e+00	MAPKAP1
Tanning	0.33	2	0	0.0	0.00	1.0e+00	C10orf32 MAPKAP1
Hair Pigment	0.23	3	1	2.2	0.00	1.0e+00	PHF5A PPP1R13B RTEL1

Associations by panel

study	tissue	# hits	% hits/tests	avg chisq
GTEx	Brain Cortex	0	0.000	1.8
GTEx	Pancreas	0	0.000	1.8
GTEx	Stomach	1	0.069	1.8
GTEx	Adipose Subcutaneous	1	0.029	1.7
GTEx	Adipose Visceral Omentum	1	0.049	1.7
GTEx	Adrenal Gland	0	0.000	1.7
GTEx	Artery Aorta	1	0.034	1.7
GTEx	Brain Caudate basal ganglia	0	0.000	1.7
GTEx	Brain Cerebellar Hemisphere	2	0.134	1.7
GTEx	Brain Cerebellum	1	0.050	1.7
GTEx	Brain Frontal Cortex BA9	0	0.000	1.7
GTEx	Brain Nucleus accumbens basal ganglia	0	0.000	1.7
GTEx	Breast Mammary Tissue	0	0.000	1.7
GTEx	Cells Transformed fibroblasts	2	0.048	1.7
GTEx	Colon Sigmoid	0	0.000	1.7
GTEx	Esophagus Gastroesophageal Junction	0	0.000	1.7
GTEx	Esophagus Muscularis	0	0.000	1.7
GTEx	Heart Atrial Appendage	0	0.000	1.7
GTEx	Heart Left Ventricle	0	0.000	1.7
GTEx	Muscle Skeletal	1	0.035	1.7
GTEx	Prostate	0	0.000	1.7
GTEx	Skin Not Sun Exposed Suprapubic	1	0.041	1.7
GTEx	Small Intestine Terminal Ileum	1	0.217	1.7
GTEx	Spleen	1	0.071	1.7
GTEx	Testis	1	0.032	1.7
GTEx	Thyroid	2	0.050	1.7
GTEx	Uterus	0	0.000	1.7
GTEx	Whole Blood	1	0.050	1.7
ROSMAP	Brain Pre-frontal Cortex	2	0.046	1.7
The Cancer Genome Atlas	Colon Adenocarcinoma	2	0.097	1.7
The Cancer Genome Atlas	Esophageal Carcinoma	0	0.000	1.7
The Cancer Genome Atlas	Head and Neck Squamous Cell Carcinoma	1	0.037	1.7
The Cancer Genome Atlas	Ovarian Serous Cystadenocarcinoma	2	0.126	1.7
The Cancer Genome Atlas	Pheochromocytoma and Paraganglioma	1	0.075	1.7
The Cancer Genome Atlas	Rectum Adenocarcinoma	1	0.145	1.7
The Cancer Genome Atlas	Stomach Adenocarcinoma	0	0.000	1.7
The Cancer Genome Atlas	Uterine Corpus Endometrial Carcinoma	0	0.000	1.7
GTEx	Artery Coronary	0	0.000	1.6
GTEx	Artery Tibial	0	0.000	1.6
GTEx	Brain Hippocampus	0	0.000	1.6
GTEx	Brain Hypothalamus	0	0.000	1.6
GTEx	Brain Putamen basal ganglia	0	0.000	1.6
GTEx	Breast Mammary Tissue (Male)	1	0.084	1.6
GTEx	Breast Mammary Tissue (Female)	0	0.000	1.6
GTEx	Cells EBV-transformed lymphocytes	1	0.070	1.6
GTEx	Colon Transverse	0	0.000	1.6
GTEx	Esophagus Mucosa	0	0.000	1.6
GTEx	Liver	1	0.139	1.6
GTEx	Lung	0	0.000	1.6
GTEx	Nerve Tibial	1	0.023	1.6
GTEx	Ovary	1	0.110	1.6
GTEx	Pituitary	0	0.000	1.6
GTEx	Skin Sun Exposed Lower leg	3	0.082	1.6
METSIM	Adipose	0	0.000	1.6
NTR	Blood	2	0.083	1.6
YFS	Blood	2	0.043	1.6
CommonMind	Brain Pre-frontal Cortex	3	0.056	1.6
The Cancer Genome Atlas	Bladder Urothelial Carcinoma	1	0.060	1.6
The Cancer Genome Atlas	Breast Invasive Carcinoma	3	0.068	1.6
The Cancer Genome Atlas	Cervical Squamous Cell Carcinoma	0	0.000	1.6
The Cancer Genome Atlas	Glioblastoma Multiforme	0	0.000	1.6
The Cancer Genome Atlas	Kidney Renal Clear Cell Carcinoma	2	0.049	1.6
The Cancer Genome Atlas	Kidney Renal Papillary Cell Carcinoma	2	0.098	1.6
The Cancer Genome Atlas	Brain Lower Grade Glioma	1	0.023	1.6
The Cancer Genome Atlas	Liver Hepatocellular Carcinoma	0	0.000	1.6
The Cancer Genome Atlas	Lung Adenocarcinoma	0	0.000	1.6
The Cancer Genome Atlas	Lung Squamous Cell Carcinoma	3	0.120	1.6
The Cancer Genome Atlas	Pancreatic Adenocarcinoma	0	0.000	1.6
The Cancer Genome Atlas	Prostate Adenocarcinoma	1	0.022	1.6
The Cancer Genome Atlas	Soft Tissue Sarcoma	0	0.000	1.6
The Cancer Genome Atlas	Skin Cutaneous Melanoma	0	0.000	1.6
The Cancer Genome Atlas	Testicular Germ Cell Tumors	2	0.156	1.6
The Cancer Genome Atlas	Thyroid Carcinoma	2	0.039	1.6
GTEx	Vagina	0	0.000	1.5